Key regions: France, India, United Kingdom, South Korea, Japan
The demand for Multiple Sclerosis Drugs in South America has been increasing steadily in recent years.
Customer preferences: Patients suffering from Multiple Sclerosis in South America prefer drugs that are effective and affordable. They also prefer drugs that have minimal side effects and those that can be administered easily.
Trends in the market: The Multiple Sclerosis Drugs market in South America is witnessing an increase in the number of new drugs being introduced. This is due to the growing demand for effective drugs and the increasing prevalence of Multiple Sclerosis in the region. The market is also seeing a shift towards the use of oral drugs as opposed to injectables. This is because oral drugs are more convenient to use and have fewer side effects.
Local special circumstances: The Multiple Sclerosis Drugs market in South America is characterized by a high level of competition among drug manufacturers. This is due to the presence of both local and international players in the market. The market is also highly regulated, and drug manufacturers have to comply with strict regulations before they can introduce their products in the market.
Underlying macroeconomic factors: The growth of the Multiple Sclerosis Drugs market in South America is being driven by several macroeconomic factors. These include the growing prevalence of Multiple Sclerosis in the region, the increasing demand for effective drugs, and the rising healthcare expenditure. The market is also benefiting from the increasing awareness about Multiple Sclerosis and the availability of advanced diagnostic tools.In conclusion, the Multiple Sclerosis Drugs market in South America is witnessing steady growth due to the increasing prevalence of the disease and the rising demand for effective drugs. The market is expected to continue growing in the coming years, driven by the introduction of new drugs and the increasing healthcare expenditure in the region.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
